In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

For those who smoke, this long-term habit can damage parts of your eye, contributing to serious conditions such as macular ...

Occasionally, treatments come along that are of greater interest to patients than to doctors.Drops for treating presbyopia ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

The following is a summary of “High Density Lipoproteins Associate with Age-Related Macular Degeneration in the All of Us Research Program,” published in the January 2025 issue of Ophthalmology by ...

Jefferies analyst issued a revised price target for 4D Molecular Therapeutics (NASDAQ:FDMT) stock, lowering it to $40 from the previous $51, while maintaining a Buy rating. Currently trading at $5.48, ...

Clearside Biomedical (CLSD) announces that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...